AZATHIOPRINE 50 MG
AZATHIOPRINE : 50 MG · DIN 02235352 · BDH INC.
Health Canada status: CANCELLED POST MARKET
What is AZATHIOPRINE?
AZATHIOPRINE 50 MG contains AZATHIOPRINE : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02235352, held by BDH INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 03-Aug-2000. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02235352 |
|---|---|
| Brand name | AZATHIOPRINE |
| Generic / active ingredient | AZATHIOPRINE : 50 MG |
| Manufacturer | BDH INC. |
| Strength | 50 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L04AX01 AZATHIOPRINE |
| AHFS class | 90:28.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 03-Aug-2000 |
| Original market date | 1998-10-08 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L04AX01 AZATHIOPRINE. 3 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-AZATHIOPRINE | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02242907 |
| IMURAN | 50 MG | TABLET | ASPEN PHARMACARE CANADA INC. | MARKETED | DIN 00004596 |
| TEVA-AZATHIOPRINE | 50 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02236819 |
| AZATHIOPRINE | 50 MG | TABLET | SANIS HEALTH INC | CANCELLED POST MARKET | DIN 02343002 |
| AZATHIOPRINE SODIUM FOR INJECTION | 100 MG | POWDER FOR SOLUTION | NOVOPHARM LIMITED | CANCELLED PRE MARKET | DIN 02231575 |
| AZATHIOPRINE-50 | 50 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02243371 |
| IMURAN | 50 MG | POWDER FOR SOLUTION | ASPEN PHARMACARE CANADA INC. | DORMANT | DIN 02244895 |
| IMURAN INJ 100MG | 100 MG | POWDER FOR SOLUTION | GLAXO WELLCOME INC. | CANCELLED POST MARKET | DIN 00337854 |
| MYLAN-AZATHIOPRINE | 50 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02231491 |
| NTP-AZATHIOPRINE | 50 MG | TABLET | TEVA CANADA LIMITED | CANCELLED PRE MARKET | DIN 02358573 |
Who else supplies AZATHIOPRINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AZATHIOPRINE appears in 113 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.